Longaevus Technologies announces Elastin spin-off following breakthrough results that could pave the way for treatment of elastin-deficiency diseases.
Longaevus Technologies, a longevity company builder with an all-round approach to reversing aging based on its multiple hallmarks, has announced the spin-off of Elastin Biosciences following breakthrough preclinical results of three of its assets. After being in stealth mode for a year, Elastin Biosciences has unveiled a significant discovery in the realm of elastin-related health; Longaevus Technologies currently has three additional companies in stealth mode.
Longevity.Technology: Elastin is a crucial protein found in the extracellular matrix of various tissues in the human body, primarily in connective tissues like skin, blood vessels and lungs. Unsurprisingly, given its name, elastin’s primary function is to provide elasticity and resilience to these tissues, allowing them to stretch and recoil back to their original shape after being stretched or compressed. It accomplishes this by forming a network of fibers that work alongside collagen, another structural protein, to maintain tissue integrity and flexibility.
However, over time, elastin naturally degrades due to various factors including cumulative exposure to UV radiation, environmental pollutants and genetic predisposition. While we can see the effects of this degradation in our skin, which can become saggy, leathery and wrinkled as we age, elastin loss can also lead to decreased vascular flexibility, something that contributes to various age-related health issues, including pulmonary emphysema, biomarkers of inflammation, aneurysmal dilatation, COPD and atherosclerosis.
Helmed by Chief Scientist Alexey Moskalev, Director of Research Alexander Fedintsev and CEO Sherif Idriss, Elastin Biosciences has successfully performed experiments in Oxford and identified three novel drug combinations that inhibit elastin degradation and foster its deposition; the experiments led yo an increase in elastin expression by 5-fold, and an improvement in aortic elasticity in aged mice in vivo.
The new research opens the door to solutions for individuals affected by elastin-deficiency related diseases and also could have the potential to significantly promote healthy longevity.
Transitioning from preclinical proof of concept to the pre-IND phase, this development indicates Elastin’s desire to be part of pioneering the future of regenerative medicine. The company also announced it has secured initial funding of $2.5 million, and bolstered by this support, it is preparing to launch a Series A funding round to further its mission and research endeavors.
The degradation of elastin, linked with a variety of health issues as well as the natural aging process, has long been on the radar of medical experts. The results announced today not only brings renewed hope for those directly afflicted by elastin-deficiency. but also spotlight a path for innovative treatments designed to bolster overall health and longevity.
The company said it is “now poised to make significant strides in regenerative medicine, ushering in a new era of treatment solutions and healthy aging.”